C12N 2710/10221
Viruses as such
Official title: Viruses as such, e.g. new isolates, mutants or their genomic sequences
C12N2710/10221 (Viruses as such) appears on 5 US grants and 4 published applications in this corpus.
Search patents in C12N- Granted patents
- 5
- Published applications
- 4
- Assignees
- 6
- Inventors
- 18
- Latest grant
- 16 Aug 2022
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2001 | 1 | 0 |
| 2002 | 0 | 0 |
| 2003 | 0 | 0 |
| 2004 | 1 | 0 |
| 2005 | 0 | 0 |
| 2006 | 0 | 0 |
| 2007 | 0 | 0 |
| 2008 | 0 | 0 |
| 2009 | 0 | 0 |
| 2010 | 0 | 0 |
| 2011 | 0 | 0 |
| 2012 | 0 | 0 |
| 2013 | 0 | 0 |
| 2014 | 0 | 1 |
| 2015 | 1 | 0 |
| 2016 | 0 | 0 |
| 2017 | 0 | 1 |
| 2018 | 0 | 0 |
| 2019 | 0 | 1 |
| 2020 | 1 | 0 |
| 2021 | 0 | 0 |
| 2022 | 1 | 0 |
| 2023 | 0 | 1 |
By publication year.
Recent patents
- Methods and compositions for performing continuous directed evolution16 Aug 2022US 11,414,677 B2Massachusetts Institute of Technology
- Vaccine in the form of a recombinant sero type 9 avian adenovirus vector1 Sep 2020US 10,758,608 B2Grupo Industrial Pecuario, S.A. De C.V.
- Non-pathogenic serotype 4 fowl adenovirus (fadv-4) and viral vector thereof1 Sep 2015US 9,119,834 B2University of Guelph
- Recombinant, replication defective CELO virus and CELO virus DNA28 Sep 2004US 6,797,506 B1Boehringer Ingelheim International GmbH
- Aviadenovirus5 Jun 2001US 6,241,991 B1Akzo Nobel N. V.
- Replication-deficient avian adenoviral vectors, their design and uses11 May 2023US 2023/0140994 A1Greffex, Inc.
- Methods and compositions for performing continuous directed evolution23 May 2019US 2019/0153472 A1Massachusetts Institute of Technology
- Vaccine in the form of a recombinant sero type 9 avian adenovirus vector17 Aug 2017US 2017/0232096 A1Grupo Industrial Pecuario, S.A. De C.V.
- Non-pathogenic serotype 4 fowl adenovirus (fadv-4) and viral vector thereof9 Jan 2014US 2014/0010834 A1University of Guelph
Most cited
By later US patents